HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effect of tolazoline on persistent hypoxemia in severe hyaline membrane disease.

Abstract
Ten critically-ill preterm infants with severe hyaline membrane disease received tolazoline because of persistent hypoxemia refractory to the administration of 100% oxygen and mechanical ventilation. Seven infants (70%) responded immediately with an increase in PaO2 greater than or equal to 20 mmHg in the umbilical arterial gas within 60 minutes after bolus infusion (1 to 2 mg/kg) of tolazoline. Twenty-four hours later after the tolazoline infusion, the FiO2 had been decreased from 1.0 to a mean of 0.82 +/- 0.16, and the MAP from 16.5 +/- 1.8 to 15.6 +/- 4.5 cm H2O. Four of 7 infants (57%) who had an immediate response survived, whereas none survived out of 3 infants who failed to respond initially. Three infants experienced relatively severe complications possibly related to tolazoline. There appears to be a place for the use of tolazoline in a severely hypoxemic infant with hyaline membrane disease who is being ventilated, and in whom arterial oxygenation cannot be improved by a further increase in the inspired oxygen concentration or by an alteration of ventilator settings.
AuthorsK I Park, R Namgung, C Lee, D G Han
JournalYonsei medical journal (Yonsei Med J) Vol. 31 Issue 2 Pg. 156-62 (Jun 1990) ISSN: 0513-5796 [Print] Korea (South)
PMID2219973 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Tolazoline
Topics
  • Humans
  • Hyaline Membrane Disease (complications)
  • Hypoxia (drug therapy)
  • Infant
  • Infant, Newborn
  • Infusions, Intravenous
  • Tolazoline (administration & dosage, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: